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Abstract 
In order to increase radio-sensitivity of human lung adenocarcinoma NCI-H1568 
cells, targeted therapy drug, erlotinib was used. The impact of radiation and 
erlotinib on cell behaviour was analyzed using three biological endpoints. 
Irradiations with γ-rays resulted in reduction of cell survival, viability and 
proliferation. Erlotinib significantly inhibited cell growth and proliferation 
capacity. Combined treatments with radiation and erlotinib showed high level of 
reduction of cell viability and proliferation. Preliminary data encourage further 




Non-small cell lung cancer (NSCLC) represents over 80% of all lung cancers. 
Radiotherapy and chemotherapy, alone or in combination are standard treatment 
strategies for this disease. The epidermal growth factor receptor (EGFR) is a 
member of the human epidermal growth factor (HER) family of receptors that is 
aberrantly expressed in a broad range of cancers including NSCLC. Ligand binding 
induces activation of tyrosine kinase (TK) domain of EGFR which leads to the 
activation of important signaling network involved in tumor cell proliferation and 
survival [1]. For this reason, blocking this signaling pathway by molecular 
targeting of EGFR is an attractive therapeutic strategy. Most targeted therapies 
include anti-EGFR monoclonal antibodies and small-molecule tyrosine kinase 
inhibitors (TKIs) [2]. Erlotinib (Tarceva) is quinazoline small-molecule inhibitor of 
HER1/EGFR tyrosine kinase approved by the United States Food and Drug 
Administration for the treatment of advanced NSCLC and pancreatic cancer [3]. 
There is evidence that radiation can activate EGFR signaling leading to accelerated 
proliferation or repopulation of tumour cells [4]. Considering the new insights into 
the role of EGFR in DNA repair through interaction with DNA-dependent protein 
kinase (DNA-PK) there is a considerable interest in using EGFR inhibitors for 
sensitizing tumours to radiotherapy in cancer patients [5].  
Trying to improve the anti-tumour activity of γ-rays by erlotinib, combined 




Materials and methods 
The NCI-H1568 cells were 
irradiated in air with 60Co γ-rays at the 
Vinča Institute of Nuclear Sciences, 
Belgrade, Serbia. Cell survival was 
assessed 7 days after irradiation in the 
dose range from 1 to 8 Gy and at the 
dose rate of ~1 Gy/min. Viability and 
proliferation were measured 7 and 14 
days post irradiation using SRB (MP 
Biomedicals, Inc) and BrdU (Roche 
Diagnostics GmbH, Mannheim, 
Germany) assays. The absorbance 
was measured at 450 and 550 nm for 
BrdU and SRB assays, respectively 
(Victor, Wallac, Turku, Finland). In 
combined treatments, following 
literature data, 5 µM erlotinib was added immediately after irradiation [6]. 
 
Results and Discussion 
Dose-dependent inhibitory effects of γ-rays are justified by clonogenic assay. 
Surviving data were fitted to the linear-quadratic model and the best fit survival 
curve is given in Figure 1. The surviving fraction at 2 Gy (SF2) is 0.78. Obtained 
data indicated high level of radio-resistance of analyzed NSCLC cells, especially to 
lower doses of γ-rays (1 and 2 Gy), while the response of NCI-H1568 cells to 
higher doses was significant (Fig. 1). Treatment of irradiated NCI-H1568 cells with 
erlotinib caused very strong inhibition of cell survival and colony formation was 
not detected. 
Based on the fact that analyzed cells are quite resistant to γ-rays, for further 
experiments dose range was extended with higher doses beyond the therapeutic 
values (12 and 16 Gy). 
Dose-dependent cell viability obtained with SRB assay, 7 days after application of 
γ-rays, ranged from 31 to 99% (Fig. 2a). NCI-H1568 cells showed strong response to 
erlotinib alone and in combination with γ-rays, with viability less than 5% (Fig. 2a). 
Similar data were obtained 14 days after irradiation, where the values were between 16 
and 90% while the number of viable cells after single and combined treatment with 
erlotinib was less than 10% (Fig.2b). For both incubation periods, good dose-
dependent response to γ-rays was observed. According to the results obtained by BrdU 
assay, cell proliferation decreases after exposure to higher doses of γ-rays. Moreover, 
treatment with erlotinib alone and in combination provokes strong inactivation of 
proliferation, with values less than 8%, as compared to control (Fig. 2c). Proliferation 
of treated cells after 14 days of incubation is given in Fig. 2d. Obtained data showed 
slightly higher proliferation of cells, not exceeding 30%, therefore indicating that the 
cells recover after applied treatments.  
Figure 1. Dose-response curve of NCI-





Figure 2. Effects of γ-rays and erlotinib on NCI-H1568 cells, 7 and 14 days after 
irradiation, estimated by SRB (a, b) and BrdU assays (c, d). 
 
Conclusion 
Presented results indicated that γ-rays inactivated NCI-H1568 cells in the dose-
dependent way. Treatment with erlotinib highly sensitized the cells to γ-rays, thus 
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